Ongoing Trials

Cancer Types


Phase I/II study of expanded, activated autologous natural killer cell infusions with trastuzumab for patients with HER2+ breast and gastric cancer

A Phase III Randomized Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (BROCADE)

Phase Ib dose-confirmation study of ASLAN001 combined with weekly paclitaxel and carboplatin in advanced solid tumours, followed by an open-label phase II study in patients with stage I-III HER2 positive breast cancer

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases

A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases treated with hormonal treatment background therapy

Phase Ib followed by Phase II study of pre-operative treatment with lenvatinib combined with letrozole in post-menopausal women with newly diagnosed hormone receptor positive breast cancer patients with measurable primary breast tumor.

Dose-dense doxorubicin/cyclophosphamide with intermittent low-dose sunitinib as neoadjuvant or first-line palliative treatment of newly diagnosed HER2 negative breast cancer patients with measurable primary breast tumor

Single Arm Phase 2 Study of Metformin and Simvastatin in addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer

A Phase II window-of-opportunity study of single agent lenvatinib in estrogen receptor positive early stage breast cancer

A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer

A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth  Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M

A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for High DLL3 expressing Small Cell Lung Cancer (SCLC) Subjects with First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy

Pilot Study of Expanded,Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Acute Leukaemia and Myelodysplatic Syndrome

Pilot Study of Autologous T Lymphocytes with Antibody-Dependent Cell Cytotoxicity in Patients with CD20-Positive B-Cell Malignancies

Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia (NKCARCD19)

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (C16021)

A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) – CHRONOS-3

Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) versus CHOP in patients with Previously Untreated Peripheral T-Cell Lymphoma.

Single institution, Phase 1 clinical trial on the safety and tolerability of a novel combination anti-leukemic therapy with Flt3 inhibitor and HDAC inhibitor in acute myeloid leukemia (AML) patients who are ineligible for intensive chemotherapy and in those who have relapsed and refractory disease

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in  Combination with Corticosteroids in Subjects with New Onset Chronic Graft versus Host Disease

Single arm, multicentre study of Carfilzomib in combination with Thalidomide and Dexamethasone (CaTD) in patients with relapsed and/or refractory multiple myeloma (RRMM)

Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study

Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer

Phase II randomized study of docetaxel with or without low-dose, short course sunitinib in the treatment of advanced solid tumors

An Investigator Sponsored Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients with Advanced or Metastatic Solid Tumor Malignancies

An open label, non-randomized, Phase I dose escalation study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1163877 in subjects with refractory, locally advanced or metastatic solid tumors

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours

STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Phase II trial of cisplatin combined with oral TS-1 in patients with advanced solid tumors with different degrees of liver dysfunction

A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies

A phase I, open-label, multi-center dose escalation study of FAZ053 as single agent and in combination with PDR001 in adult patients with advanced malignancies

A Phase I, First-in-Human Study of PRL3-ZUMAB In Advanced, Solid Tumors

Phase 1, Open Label, Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients with Advanced Solid Tumors

A First-in-human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA To Investigate Its Safety And Tolerability In Patients With Advanced Liver Cancer

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and Lymphomas

Feasibility study of intraperitoneal paclitaxel with standard-of-care oxalipatin and capecitabine in patients with advanced gastric cancer

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer

A two-part phase 2/3 multicentre, double-lind, randomised, placebo controlled study of varlitinib plus mFOLFOX6 versus placebo plus mFOLFOX6 in subjects with HER1/HER2 co-expressing advanced or metastatic gastric cancer without prior exposure to systemic therapy

A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma

A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy

A Phase III Study of Pembrolizumab (MK-3475) vs Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (Keynote-177)

A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC): STOP-HCC

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

A multicenter, phase 1B/2 study of Varlitinib in combination with Gemcitabine and Cisplatin for treatment naïve advanced or metastatic biliary tract cancer

Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II study

Phase 1b open label dose assessment study of ASLAN001 (Varlitinib) in patients with advance/ metastatic hepatocellular carcinoma (HCC) with an expansion cohort in HCC patients expressing HER3 who have progressed on first line Sorafenib.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine In Patients With Advanced or Metastatic Biliary Tract Cancer As Second-Line Systematic Therapy

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

Phase II open-label study evaluating two loading regimens of sunitinib or bevacizumab alternating with cisplatin and gemcitabine as systemic therapy for locally advanced or metastatic nasopharyngeal carcinoma (NPC)

A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) – (KEYNOTE 122)

Reactivating NK cells in treating refractory head and neck cancer

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally advanced stage IV or locally recurrent/metastatic Nasopharyngeal Carcinoma

Randomized, Double-blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer – A Phase III Trial

Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel for platinum resistant ovarian cancer with predominant non-visceral abdominal disease

A Randomized,Open-label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotheray in Patients with Previously Untreated Epithelial Ovarian Cancer

Phase II study of Intravenous Vinorelbine in Patients with Relapsed Platinum Resistant or Refractory C5 High Grade Serous Ovarian Cancer (VIP)

A Multicentre Phase II randomised trial of DURVALUMAB versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas (MOCCA)

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Soft Tissue Sarcomas

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification

A Phase III, Multicenter, Randomized, Placebo-controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination with Platinum-based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma